March 1, 2017Open Access

Blinatumomab versus Quimioterapia para Leucemia Linfoblástica Aguda Avançada

Key Points

Key points are not available for this paper at this time.

Abstract

O tratamento com blinatumomab resultou em sobrevida global significativamente mais longa do que a quimioterapia entre pacientes adultos com LLA de precursores de células B recidivante ou refratária. (Financiado pela Amgen; TOWER ClinicalTrials.gov número, NCT02013167).

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Hagop Kantarjian

Anthony S. Stein

Nicola Gökbuget

Journals

New England Journal of Medicine

Actions

Institutions

University College London

Goethe University Frankfurt

Universitat Autònoma de Barcelona

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Blinatumomab versus Quimioterapia para Leucemia Linfoblástica Aguda Avançada

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study